Van:	CCMO - Bevoegde Instantie / Competent Authority
Aan:	ccmo_frontoffice; ccmo_eudract
Onderwerp:	FW: CRTH258C2302 - NL68931.100.19 - Declaration of the Local and Global end of trial: Early Termination
Datum:	dinsdag 10 augustus 2021 07:01:44
Bijlagen:	A1 NL68931.100.19 Cover Letter 09Aug2021.pdf B7 Declaration of the End of Trial Form 09Aug2021.pdf

Einde studie voor Marjolein.

Groet, 5.1.2.e

Van: 5.1.2.e @novartis.com> **Namens** 5.1.2.e
Verzonden: maandag 9 augustus 2021 15:49
Aan: CCMO - Bevoegde Instantie / Competent Authority <bi@ccmo.nl>
Onderwerp: CRTH258C2302 - NL68931.100.19 - Declaration of the Local and Global end of trial: Early Termination

EudraCT no.: 2018-001788-21
Protocol code: CRTH258C2302
ToetsingOnline dossier no.: NL68931.100.19

Dear Madam/Sir,

On behalf of the Sponsor **Novartis Pharma AG**, Parexel International Romania s.r .l. herewith notifies the early end of the above referenced clinical trial.

We would like to inform you that Novartis has decided to early terminate the clinical trial and Global Last Patient Last Visit (LPLV) was achieved globally on 26-July-2021

The last subject last visit in The Netherlands occurred on 23-Jun-2021.

We trust this notification fulfils your requirements, however, in the event of any queries, please do not hesitate to contact us.

Yours faithfully,

Parexel International Romania s.r.l
5.1.2.e on behalf of 5.1.2.e
5.1.2.e
Metropolis Center, Str. Grigore Alexandrescu
No. 89-97, Bucharest,
Romania, 010624
Tel: +40 5.1.2.e
Fax: +40 5.1.2.e
Email: 5.1.2.e @Novartis.com